NYSE American - Nasdaq Real Time Price • USD
VolitionRx Limited (VNRX)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 7:48 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 4 | 4 | 4 | 3 |
Avg. Estimate | -0.11 | -0.11 | -0.41 | -0.32 |
Low Estimate | -0.12 | -0.12 | -0.48 | -0.41 |
High Estimate | -0.1 | -0.1 | -0.35 | -0.25 |
Year Ago EPS | -0.15 | -0.14 | -0.5 | -0.41 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 4 | 4 | 4 | 3 |
Avg. Estimate | 390k | 630k | 3.63M | 15.59M |
Low Estimate | 270k | 470k | 3M | 8.3M |
High Estimate | 500k | 900k | 4.7M | 21.8M |
Year Ago Sales | 420k | 216k | 775k | 3.63M |
Sales Growth (year/est) | -7.10% | 191.70% | 368.40% | 329.50% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.14 | -0.15 | -0.13 | -0.11 |
EPS Actual | -0.15 | -0.14 | -0.11 | -0.11 |
Difference | -0.01 | 0.01 | 0.02 | 0 |
Surprise % | -7.10% | 6.70% | 15.40% | 0.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.11 | -0.11 | -0.41 | -0.32 |
7 Days Ago | -0.11 | -0.11 | -0.41 | -0.32 |
30 Days Ago | -0.11 | -0.11 | -0.39 | -0.32 |
60 Days Ago | -0.11 | -0.11 | -0.39 | -0.32 |
90 Days Ago | -0.11 | -0.11 | -0.39 | -0.32 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | VNRX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 26.70% | -- | -- | 1.50% |
Next Qtr. | 21.40% | -- | -- | 11.40% |
Current Year | 18.00% | -- | -- | 5.20% |
Next Year | 22.00% | -- | -- | 13.40% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/27/2024 |
Maintains | EF Hutton: Buy to Buy | 3/27/2024 |
Reiterates | EF Hutton: Buy to Buy | 1/2/2024 |
Reiterates | EF Hutton: Buy to Buy | 11/21/2023 |
Maintains | Cantor Fitzgerald: Overweight to Overweight | 11/16/2023 |
Initiated | EF Hutton: Buy | 10/30/2023 |
Related Tickers
ISPC iSpecimen Inc.
0.2778
-5.86%
PRPH ProPhase Labs, Inc.
5.06
-1.94%
TTOO T2 Biosystems, Inc.
2.7600
+1.47%
NDRA ENDRA Life Sciences Inc.
0.2599
+2.16%
OCX OncoCyte Corporation
2.4600
+0.20%
ME 23andMe Holding Co.
0.4671
-5.39%
BIAF bioAffinity Technologies, Inc.
2.4500
-5.41%
OPK OPKO Health, Inc.
1.2300
-1.60%
P8A.SI Cordlife Group Limited
0.1260
0.00%
CDNA CareDx, Inc
7.98
-3.04%